



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/731,672	12/09/2003	Shulamit Levenberg	0492611-0530/MIT-10077	6356

24280 7590 06/18/2007
CHOATE, HALL & STEWART LLP
TWO INTERNATIONAL PLACE
BOSTON, MA 02110

EXAMINER

SGAGIAS, MAGDALENE K

ART UNIT	PAPER NUMBER
----------	--------------

1632

MAIL DATE	DELIVERY MODE
-----------	---------------

06/18/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/731,672

Applicant(s)

LEVENBERG ET AL.

Examiner

Magdalene K. Sgagias

Art Unit

1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on 21 March 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-5, 7-11, 13-25, 27-34, 36-44, 47-50 and 59-74 is/are pending in the application.
- 4a) Of the above claim(s) 59-70 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-5, 7-11, 13-25, 27-34, 36-44, 47-50, 71-74 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____.

DETAILED ACTION

Applicant's arguments filed 3/21/07 have been fully considered but they are not persuasive. The amendment has been entered. Claims 1-5, 7-11, 13-25, 27-34, 36-44, 47-50, 59-74 are pending. Claims 12, 26, 35, 45-46, 51-58 are canceled. Claims 59-70 are withdrawn. Claims 1-5, 7-11, 13-25, 27-34, 36-44, 47-50, 71-74 are under consideration.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-5, 7-11, 14-15 rejection under 35 U.S.C. 102(a) is withdrawn.

Claims 1-2 rejection under 35 U.S.C. 102(b) is withdrawn.

Claims **1-5, 7-11, 13-22** are rejected under 35 U.S.C. 102(a) as being anticipated by **Levenberg et al**, (PNAS, 99(7): 4391-4396, 2002).

Levenberg teaches a tissue-engineering construct, comprising human embryonic stem cells, a three-dimensional cell support matrix, wherein cells are exposed to at least one growth factor in the endothelial growth medium EGM-2 which contains growth factors cytokines and supplements and wherein embryonic stem cells differentiate into vascular-like structures (abstract, p 4396, 2nd column under cell culture, p 4393) (**claims 1-3**).

Levenberg also teaches a tissue engineered construct wherein the cell support matrix comprises poly-(L-lactic acid) (PLLA) and poly lactic-glycolic acid (PLGA) mixed 1:1 (p 4392, 2nd column) (**claims 4-11**) .

Levenberg also teaches the cell support matrix is biodegradable (p 4392, 2nd column) (**claims 14-15**).

Levenberg also teaches the cells were mixed 1:1 mix of culture medium and matrigel polymer sponges and the cell support matrix has a sponge shape (p 4392, 2nd column) (**claims 17-18, 22**).

Levenberg teaches the differentiation of human embryonic stem cells into endothelial cells forming vascular-like structures (abstract and p 4393 and figure 2). **Levenberg** teaches the assembly of developing vascular-like structures could be observed during EBs outgrowth; as soon as the cells acquired the set of endothelial markers. The data also indicate that the capillary area in the EBs increased during subsequent maturation steps up to day 13, starting from cell clusters that later sprout into capillary-like structures and eventually become organized in a network-like arrangement (**claim 1**).

Further, the tissue engineered construct of **Levenberg** would inherently be resistant to contractile forces exerted by the stem cells and at least one growth factor selected to promote differentiation of the stem cells into smooth muscle cells. A product and its properties cannot be separated. The tissue engineered construct of **Levenberg** would inherently contain smooth muscle cells as in the claimed method, since a three dimensional vascular network is composed of endothelial and smooth muscle cells around a lumen. As the three dimensional matrix of **Levenberg** cannot be distinguished from those claimed, the properties of the tissue engineering construct of **Levenberg** and those claimed would have the same properties.

Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a *prima facie* case of either anticipation or obviousness has been established. *In re Best*, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). "When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not." *In re Spada*, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Therefore, the *prima facie* case can be rebutted by evidence showing that the prior art products do not necessarily possess the characteristics of the claimed product. *In re Best*, 562 F.2d at 1255, 195 USPQ at 433. See also *Titanium Metals Corp. v. Banner*, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985), *In re Ludtke*, 441 F.2d 660, 169 USPQ 563 (CCPA 1971), *Northam Warren Corp. v. D. F. Newfield Co.*, 7 F. Supp. 773, 22 USPQ 313 (E.D.N.Y. 1934) and MPEP 2112.01.

"[T]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art's functioning, does not render the old composition patentably new to the discoverer." *Atlas Powder Co. v. Ireco Inc.*, 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of a new use, new function or unknown property, which is inherently present in the prior art, does not necessarily make the claim patentable. *In re Best*, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977).

Furthermore, there is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the time of invention, but only that the subject matter is in fact inherent in the prior art reference. *Schering Corp. v. Geneva Pharm. Inc.*, 339 F.3d 1373, 1377, 67 USPQ2d 1664, 1668 (Fed. Cir. 2003).

Applicant is referred to MPEP 2112.

Thus, **Levenberg** et al, clearly anticipates the claimed invention.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-5, 7-11, 13-25, 27-34, 36-44, 47-50 rejection under 35 U.S.C. 103(a) as being unpatentable over Naughton et al, (US 5,962,325) in view of Griffith et al, (Science, 295: 1009-1014, 2002) is withdrawn.

Claims 53-54, 57-58 rejection under 35 U.S.C. 103(a) as being unpatentable over Levenberg, (PNAS, 99(7): 439104396, 2002) in view of Guan et al, (Cell Tissue Res, (305: 171-176, 2001) is withdrawn.

Claims 53-54, 56-58 rejection under 35 U.S.C. 103(a) as being unpatentable over Levenberg, (PNAS, 99(7): 439104396, 2002) in view of Benvenisty et al, (US 2002/0146678) is withdrawn.

Claims **1-5, 7-11, 13-25, 27-34, 36-42, 47-50**, are rejected under 35 U.S.C. 103(a) as being unpatentable over **Levenberg et al**, (PNAS, 99(7): 4391-4396, 2002) in view of **Benvenisty et al**, (US 2002/0146678).

Levenberg teaches a tissue-engineering construct, comprising human embryonic stem cells, a three-dimensional cell support matrix, wherein cells are exposed to at least one growth factor in the endothelial growth medium EGM-2 which contains growth factors cytokines and

supplements and wherein embryonic stem cells differentiate into vascular-like structures (abstract, p 4396, 2nd column under cell culture, p 4393) (**claims 1-3**).

Levenberg also teaches a tissue engineered construct wherein the cell support matrix comprises poly-(L-lactic acid) (PLLA) and poly lactic-glycolic acid (PLGA) mixed 1:1 (p 4392, 2nd column) (**claims 4-11**) .

Levenberg also teaches the cell support matrix is biodegradable (p 4392, 2nd column) (**claims 14-15**).

Levenberg also teaches the cells were mixed 1:1 mix of culture medium and matrigel polymer sponges and the cell support matrix has a sponge shape (p 4392, 2nd column) (**claims 17-18, 22**).

Levenberg teaches the differentiation of human embryonic stem cells into endothelial cells forming vascular-like structures (abstract and p 4393 and figure 2). **Levenberg** teaches the assembly of developing vascular-like structures could be observed during EBs outgrowth, as soon as the cells acquired the set of endothelial markers. The data also indicate that the capillary area in the EBs increased during subsequent maturation steps up to day 13, starting from cell clusters that later sprout into capillary-like structures and eventually become organized in a network-like arrangement (**claim 1**). **Levenberg** does not teach the addition of retinoic acid thus, anticipating the growth factor is substantially free of retinoic acid. **Levenberg** differs from the claimed invention for not teaching exposing the embryonic stem cells to activin A.

However, at the time the claimed invention was made, **Benvenisty et al**, teach methods for mapping a pathway of differentiation of a population of embryonic stem cells which includes exposing the cells to Activin A and wherein cells differentiated into muscle-like syncytium (page 7, 2nd column, example 2). **Benvenisty et al**, reports while human embryonic stem cells have been recovered from human embryos produced by in vitro fertilization, the formation of

Art Unit: 1632

embryoid bodies from human primates and from humans has been problematic and the formation of embryoid bodies from primates is inconsistent and asynchronous (p 1, 1st column).

Benvenisty et al, have also suggested it is desirable to have tools to analyze and compare pathways indifferent mammals and to combine those these tools with a methodology that permits the isolation, preservation and cultivation of embryonic stem cells from mammals for transplantation in numerous human pathologies as a component in biomedical engineering (p 1 columns 1-2). As such, **Benvenisty** provides sufficient motivation for one of ordinary skill in the art to apply the three-dimensional cell support system of **Levenberg** exposing the cells to activin A wherein using human embryonic stem cells to analyze and compare pathways indifferent mammals and to combine those these tools with a methodology that permits the isolation, preservation and cultivation of embryonic stem cells from mammals for transplantation in numerous human pathologies as a component in biomedical engineering.

Accordingly, in view of the teachings of **Benvenisty et al**, it would have been obvious for one of ordinary skill in the art, at the time the claimed invention was made, to modify the three dimensional construct of **Levenberg** by use human embryonic stem cells exposed to activin A with a reasonable expectation of success. One of ordinary skill in the art would have been sufficiently motivated to make such a modification as it was taught by **Levenberg** exposing the cells to activin A wherein using human embryonic stem cells to analyze and compare pathways in different mammals and to combine those these tools with a methodology that permits the isolation, preservation and cultivation of embryonic stem cells from mammals for transplantation in numerous human pathologies as a component in biomedical engineering, in particular as **Levenberg** suggested it is desirable to have tools to analyze and compare pathways indifferent mammals and to combine those these tools with a methodology that permits the isolation,

preservation and cultivation of embryonic stem cells from mammals for transplantation in numerous human pathologies as a component in biomedical engineering.

Thus, the claimed invention as a whole is clearly prima facie obvious in the absence of evidence to the contrary.

Claims **1-5, 7-11, 13-25, 27-34, 36-44, 47-50, 71-74** are rejected under 35 U.S.C. 103(a) as being unpatentable over **Levenberg et al**, (PNAS, 99(7): 4391-4396, 2002) in view of **Benvenisty et al**, (US 2002/0146678), and further in view of **Kojima et al**, (Experimental Cell Research, 206(2): 152-156, 1993).

The 103 rejection of claim **1-5, 7-11, 13-25, 27-34, 36-42, 47-50**, as being unpatentable over Levenberg taken with Benvenisty is applied here as indicated above.

Levenberg taken with Benvenity do not teach a tissue engineered construct with embryonic stem cells in serum-free medium and IGF.

However, at the time the invention was made, Kojima is an exemplified prior art that teaches that it is routine or well-established in the art to employ serum-deprived cells were incubated with activin A, nuclear labeling of bromodeoxyuridine occurred after a 12-h lag period. The effect of activin A on nuclear labeling was dose-dependent, being maximal at 10^{-9} M. Activin A also increased the number of VSMC after 30 h of incubation. Insulin-like growth factor-1 (IGF-1) had only a small effect on nuclear labeling by itself but the effects of IGF-1 and activin A were additive. When quiescent VSMC were treated with activin A for 4 h, the effect of subsequent IGF-1 was markedly enhanced. Furthermore, activin A induced an autocrine production of IGF-1 in VSMC. In contrast to these positive effects on cell growth, activin A was rather inhibitory to the action of IGF-1 in activin-primed cells. In addition, activin A inhibited platelet-derived growth factor-induced nuclear labeling. These results indicate that activin A

Art Unit: 1632

modifies growth of VSMC by complex mechanisms involving autocrine production of IGF-1 and modification of the action of IGF-1 (abstract).

Thus, it would also have been obvious for one of ordinary skill in the art of tissue engineering constructs for transplantation to further employ serum free conditions and IGF available in the art in tissue engineering of the combined cited reference. One of ordinary skill in the art would have been motivated to employ serum free and IGF conditions in order to compare pathways indifferent mammals and to combine those these tools with a methodology that permits the isolation, preservation and cultivation of embryonic stem cells from mammals for transplantation in numerous human pathologies as a component in biomedical engineering when administered in vivo. One of ordinary skill in the art would have reasonably expected that further inclusions of serum free and IGF are routinely employed in the art and can help to further delineate VSMC by complex mechanisms involving autocrine production of IGF-1 and modification of the action of IGF, particularly in view of the totality of the prior art at the time the invention was made.

Thus, the claimed invention was prima facie obvious.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

The term "substantially free" in claim 72 is a relative term which renders the claim indefinite. The term "substantially" is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The concentration of retinoic acid is an all or none principle that is, it either exists or not exists.

Art Unit: 1632

The term "substantially free" in claim 74 is a relative term which renders the claim indefinite. The term "substantially" is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The concentration of retinoic acid is an all or none principle that is, it either exists or not exists.


Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Magdalene K. Sgagias whose telephone number is (571) 272-3305. The examiner can normally be reached on Monday through Friday from 9:00 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras, Jr., can be reached on (571) 272-4517. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Magdalene K. Sgagias, Ph.D.
Art Unit 1632


DEBORAH CROUCH
PRIMARY EXAMINER
GROUP 1800-1630